<DOC>
	<DOCNO>NCT01342146</DOCNO>
	<brief_summary>The purpose multicenter , randomize , open-label , control phase II study determine whether pegylated recombinant human growth hormone effective treatment child growth hormone deficiency .</brief_summary>
	<brief_title>Efficiency Safety Study Pegylated Somatropin Treat Growth Hormone Deficiency Children</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>height less two standard deviation ( SD ) median height individual age height , growth velocity ( GV ) ≤4 cm/yr , GH peak concentration &lt; 7 ng/ml two different provocative test , bone age ( BA ; ≤9 year girls ≤10 year boys ) least 2 year less his/her chronological age ( CA ) ; preadolescence ( Tanner stage 1 ) CA &gt; 3 year ; height value record 3 month start GH treatment calculate pretreatment GV ; receive prior GH treatment . sign informed consent patient severe cardiopulmonary patient hematological disease current past history malignant tumor immunodeficiency disease mental disease patient positive hepatitis B eantibody ( HBeAb ) hepatitis B surface antigen ( HBsAg ) hepatitis B e antigen ( HBeAg ) patient growth disorder , Turner syndrome constitutional delay growth puberty , Laron syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>pegylated Somatropin</keyword>
	<keyword>PEG-GH</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>PEG-rhGH</keyword>
	<keyword>Growth hormone deficiency ( GHD )</keyword>
	<keyword>Phase 2 study</keyword>
</DOC>